1 Gilead Sciences.
2 Bristol Myers Squibb (BMS).
* Corresponding Author
World Journal of Advanced Research and Reviews, 2021, 12(03), 820–830
Article DOI:10.30574/wjarr.2021.12.3.0703
Received on 11 November 2021; revised on 26 December 2021; accepted on 30 December 2021
Background: Ulcerative colitis (UC) trials integrate symptom diaries and endoscopic assessment, often under distinct visit windows and missingness rules. The SELECTION trial of filgotinib provides a published clinical context, but reproducible endpoint programming requires separate, auditable specifications.
Objective: To present a component-first, ADaM-oriented implementation framework and experimentally assess the sensitivity of an illustrative UC remission classification to a change in diary eligibility.
Methods: We specified source-to-analysis lineage, visit anchoring, component aggregation, endpoint construction and validation controls, informed by public clinical and regulatory literature. Using a fixed random seed (20261101), we generated 500 entirely synthetic profiles with seven preassessment diary days and artificial baseline and endoscopic subscores. For each symptom component, we required four valid diary days and applied round-half-up to the mean. Two scenarios retained all seven preceding days or omitted day −1, respectively.
Results: Of 500 profiles, 491 were classifiable under both scenarios. Remission classification differed for 21/491 (4.3%); 92/491 (18.7%) met the illustrative remission condition with all days versus 89/491 (18.1%) after excluding day −1. Unclassifiable profiles numbered 1 and 9, respectively, among all 500.
Conclusions: Altering diary eligibility can change derived classifications and evaluability in a constructed computational example. Results are not clinical estimates, a replication of SELECTION, or validation of a regulatory endpoint. The framework supports transparent rule testing and traceability prior to protocol-specific implementation.
Ulcerative Colitis, Mayo Score, Diary Data, Electronic Patient-Reported Outcomes; Endoscopy, Adam, Missing Data; Adam; Synthetic Data; Reprdoucibility; Sensitivity Analysis.
Preview Article PDF
Jyoti (Jo) Agarwal and Satyakam Singh. IMPLEMENTING ULCERATIVE COLITIS DIARY AND ENDOSCOPIC EFFICACY ENDPOINTS (A REPRODUCIBLE ADAM-ORIENTED FRAMEWORK AND SYNTHETIC-DATA SENSITIVITY STUDY). World Journal of Advanced Research and Reviews, 2021, 12(03), 820–830. Article DOI: https://doi.org/10.30574/wjarr.2021.12.3.0703